← Back to all trials
Enrolling By Invitation
NCT05708326
A Case Crossover Study of Intermittent Fasting in CLL/SLL
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Sex: All
Ages: 19 Years – 85 Years
Phase: NA
Enrollment: 8
Sponsor: British Columbia Cancer Agency
Location: Canada
Summary
The purpose of this study is to compare the 16/8 intermittent fasting method with the 5:2 Method in a subset of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma at BC Cancer- Victoria.
The purpose is to find out which is the preferred method by patients and which has the greatest effect on:cancer cells (lymphyocyte count),metabolism (autophagy activation),inflammation (CRP),gut microbiome (metabolomic analysis).Participants will have already completed our previous trial, "Intermittent Fasting in CLL/SLL" (ClinicalTrials.gov
Identifier: NCT04626843) where they followed the 16/8 Fasting Method followed by a minimum of a 3 months washout period, and will now follow the 5:2 Method for 90 days.
The same samples and outcome measures will be collected in order to directly compare the two diets in the same patient cohort.
Eligibility Criteria
Inclusion Criteria:Diagnosis of CLL or SLLAge < 85 yearsPeripheral blood lymphocytes >20 x 109/LHemoglobin > 90g/LPlatelets > 90 x 10*9/LBMI of >=20kg/m2ECOG Performance Status >=2Completion of "IF in CLL/SLL Study" (ClinicalTrials.gov
Identifier: NCT04626843) followed by minimum of 3 month ad libitum eatingExclusion Criteria:Patient unable to give consentPatient on medications required to be taken with food during the fasting windowPregnancyDiabetes mellitusBMI drop to < 18.5kg/m2 at any time during studyAnti-lymphoma therapy within the past 3 monthsExpected to require initiation of anti-lymphoma therapy within the next 3 months
Source: ClinicalTrials.gov (NCT05708326). StuddyBuddy aggregates publicly available trial information.
